Table 3. Response and survival following CL56 and subsequent response to further hormone therapy.

Median no. of cycles:	2 (range 1–6)
Response to CL56
CR	1
PR	2
SD	17
PD	12
NE	5
Response rate
	3/32 (10%)
Stabilisation rate (SD or better)
	20/32 (63%)
Symptomatic improvement (24 evaluable)
No	13
Yes	11
Alk Phos response by week 8 (14 evaluable)
No	11
Yes	3
Median survival	7.1 months (95% CI 6.2–8.0)
Median time to progression	3.6 months (95% CI 2.3–4.9)
PF at 6 months	5/37
Median survival following AI	23.5 months (95% CI 17.2–29.8)
Post-CL56 hormones
Yes	17
Response to post-CL56 hormone therapy
Yes	9
>50%	3